Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarker and AI-driven diagnostics for chronic low back pain, announced the appointment of Daniel Keefe as Commercial Director, Western U.S. Keefe will lead commercial efforts across the Western region, building on the company's existing footprint and supporting continued adoption of Nociscan, its cloud-based platform that noninvasively helps physicians distinguish between painful and nonpainful lumbar discs.
The appointment comes as Aclarion reports triple-digit growth in Nociscan utilization, reflecting increasing demand from spine surgeons and hospitals. The company has established a growing presence across the Western U.S., with engagements spanning academic institutions and high-volume private practice spine centers. Keefe's role is expected to deepen adoption in this key strategic region.
Brent Ness, CEO of Aclarion, stated, 'Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies. His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan.'
Keefe brings over 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across the Northern California region. Throughout his career, he has demonstrated success in building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments.
'I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,' said Keefe. 'The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.'
Chronic low back pain affects an estimated 266 million people worldwide. Aclarion's Nociscan is the first evidence-supported, cloud-based platform to noninvasively help physicians identify painful discs by quantifying chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated. For more information on Nociscan, visit www.aclarion.com.
